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Abstract: CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy) is caused by mutations in the NOTCH3 gene, affecting the number of cysteines
in the extracellular domain of the receptor, causing protein misfolding and receptor aggregation.
The pathogenic role of cysteine-sparing NOTCH3 missense mutations in patients with typical
clinical CADASIL syndrome is unknown. The aim of this article is to describe these mutations
to clarify if any could be potentially pathogenic. Articles on cysteine-sparing NOTCH3 missense
mutations in patients with clinical suspicion of CADASIL were reviewed. Mutations were considered
potentially pathogenic if patients had: (a) typical clinical CADASIL syndrome; (b) diffuse white matter
hyperintensities; (c) the 33 NOTCH3 exons analyzed; (d) mutations that were not polymorphisms;
and (e) Granular osmiophilic material (GOM) deposits in the skin biopsy. Twenty-five different
mutations were listed. Four fulfill the above criteria: p.R61W; p.R75P; p.D80G; and p.R213K.
Patients carrying these mutations had typical clinical CADASIL syndrome and diffuse white matter
hyperintensities, mostly without anterior temporal pole involvement. Cysteine-sparing NOTCH3
missense mutations are associated with typical clinical CADASIL syndrome and typical magnetic
resonance imaging (MRI) findings, although with less involvement of the anterior temporal lobe.
Hence, these mutations should be further studied to confirm their pathological role in CADASIL.
Keywords: CADASIL; cysteine; NOTCH3; mutation; temporal pole
1. Introduction
CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy) is an inherited systemic arterial vessel disease caused by mutations in the
NOTCH3 gene, located on the 19p13 chromosome [1,2], which encodes a transmembrane receptor that
is mainly expressed in the smooth muscle cells of blood vessels and pericytes [3].
This receptor has three domains: (1) a large extracellular domain (ECD) with 34 epidermal
growth factor (EGF)-like repeats encoded by exons 2–24, where NOTCH3 mutations are typically
located; (2) a transmembrane domain; and (3) an intracellular domain (ICD). Each EGF-like repeat
contains six cysteines that form three disulfide bonds, which contribute significantly to the protein’s
tertiary structure.
Int. J. Mol. Sci. 2017, 18, 1964; doi:10.3390/ijms18091964 www.mdpi.com/journal/ijms
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Pathogenic mutations in CADASIL are dominant; the presence of only one mutation in one of
both alleles is the cause of the pathology. The pathogenic mutations are associated with changes in
the number of cysteines, these changes cause an odd number of cysteines, leading to a misfolding of
the receptor, enhanced formation of oligomers and ECD aggregation, facilitated by crosslinking of
sulfhydryl groups [4–6]. This ECD aggregation is considered to be the main pathogenic mechanism
of the disease. In terms of NOTCH3 activity, classic mutations have been described with normal
or decreased NOTCH3 activity. Nevertheless, its role in the pathogenic mechanism is controversial,
and several authors have shown that altered NOTCH3 function is not the primary determinant of the
disease [7–9].
The main symptoms of CADASIL are migraine, psychiatric disorders, recurrent small subcortical
infarctions, and dementia [10]. The average age at stroke onset is approximately 46 years, although
recent studies have described an older onset, at 52 years for males and 57 for females [11]; for dementia,
the average age at onset is 55 [12].
Magnetic resonance imaging (MRI) and histopathology show small subcortical infarctions and
confluent white matter hyperintensities (WMH), mostly in periventricular locations and with additional
involvement of the anterior temporal pole and the external capsule [13].
It has been described elsewhere that WMH in the temporal pole have 89–95% sensitivity and
80–86% specificity for CADASIL diagnosis in Caucasian patients [14], and up to 95% of these
patients have this alteration [15]. Nevertheless, in Asian populations the prevalence of temporal
pole involvement is only between 44.8–71% [16].
Additionally, it is typical to find granular osmiophilic material (GOM), consisting of parts of the
extracellular domain of NOTCH3 [17], in the extracellular space and located close to the cell surface
in smooth-muscle cells [18]. The presence of GOM has 45–96% sensitivity and 100% specificity for
CADASIL diagnosis [15,19], but the pathological role of GOM is still debated.
Recent studies have found that mutations that do not affect the number of cysteines (unlike the
typical mutations) seem to be associated with clinical CADASIL syndrome. However, the pathogenic
role of these mutations is uncertain.
Therefore, this is a systematic review of those studies in which patients with a clinical suspicion
of CADASIL and cysteine-sparing NOTCH3 missense mutations have been described. The aims of
this article are to: (1) find data in the literature and in databases relating to cysteine-sparing NOTCH3
missense mutations observed in patients with typical clinical CADASIL syndrome; (2) describe the
epidemiological characteristics of these patients; (3) determine whether these mutations could be
considered potentially pathogenic.
There is not a consensus to determine whether a mutation can be considered pathogenic.
Depending on the disease the presence of a missense mutation that has not been described previously
in healthy subjects and with bioinformatic data supporting the pathogenicity is enough to consider
a mutation the cause of the disease [20]. However this is not the case for other diseases and more
analysis should be performed. For instance in neurodegenerative disorders there are studies that
have analyzed the conservation of the residue during the evolution or have analyzed the presence of
described mutations involving the same Wild-type amino acid [21,22].
In the case of CADASIL, the presence of GOM is very important because this finding indicates
that the patient has CADASIL. The other critical point is to analyze all the exons of the NOTCH3 gene
to find the mutation that causes the pathology. In our systematic review we have considered these two
analyzes among others to identify a pathogenic mutation.
2. Results
Of the 244 studies reviewed, 16 fulfilled the inclusion/exclusion criteria and 34 index cases were
described, with 25 different mutations. Twelve out of the 18 patients were female (67%) and six were
male (33%); 17 of the total number of patients were European (50%), 14 were Asian (41%), two patients
were from Oceania and one was North-American (Table 1).
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Table 1. Mutations found that do not affect cysteine amino acids.
Number Mutation Replaced Substitution Exon Sequencing MAF (ExAC) MAF (1000 Genomes) Author
1 p.R61W Arg Trp 2 33 exons 0.00007471 - Brass [23]
2 p.R75P Arg Pro 3 Exon: 3, 4, 11, 18; intron 0 0 Kim [24]
3 p.R75P Arg Pro 3 Exon: 3, 4, 11, 18; intron 0 0 Kim [24]
4 p.R75P Arg Pro 3 Exon: 3, 4, 11, 18; intron 0 0 Kim [24]
5 p.R75P Arg Pro 3 33 exons, promotor 0 0 Mizuno [25]
6 p.R75P Arg Pro 3 33 exons, promotor 0 0 Mizuno [25]
7 p.R75P Arg Pro 3 Exon: 2–24 0 0 Wang [26]
8 p.D80G Asp Gly 3 33 exons 0 0 Wollenweber [27]
9 p.R107W Arg Trp 3 Exon: 2–23 0.00001750 - Ungaro [28]
10 p.G149V Gly Val 4 33 exons, intron 0 0 Ge [29]
11 p.Q151E Gln Glu 4 Exon: 2–23 0.00005703 - Ungaro [28]
12 p.Q151E Gln Glu 4 Exon: 2–6, 8, 11, 14, 18, 19, 22, 23; intron 0.00005703 - Ampuero [30]
13 p.H170R His Arg 4 Exon: 2–6, 8, 11, 14, 18, 19, 22, 23; intron 0.001917 0.0014 Ampuero [30]
14 p.H170R His Arg 4 Exon: 2, 3, 4, 11, 18, 19 0.001917 0.0014 Roy [31]
15 p.A198T Ala Thr 4 Exon: 2–23 0.00002513 - Ungaro [28]
16 p.A202V Ala Val 4 Exon: 2, 3, 4, 11, 18, 19 0.00001672 - Roy [31]
17 p.R207H Arg His 4 Exon: 2–23 0.00001664 0.0004 Ungaro [28]
18 p.R213K Arg Lys 4 - 0 0 Uchino [32]
19 p.R213K Arg Lys 4 33 exons 0 0 Santa [33]
20 p.V237M Val Met 5 - 0.0002239 0.0008 Uchino [32]
21 p.V252M Val Met 5 Exon: 2–23; intron 0.00002493 - Abramycheva [34]
22 p.E309K Glu Lys 6 Exon: 2–23 0 0 Ungaro [28]
23 p.S497L Ser Leu 9 Exon: 2–23; intron 0.01234 0.0074 Abramycheva [34]
24 p.T577A Thr Ala 11 - 0.00001669 0 Ferreira [35]
25 p.R592S Arg Ser 11 Exon: 2–23 0.00006714 - Ungaro [28]
26 p.V644D Val Asp 12 Exon: 2–23 0.0007013 0.0002 Ungaro [28]
27 p.S978R Ser Arg 18 - 0.0004606 0.0004 Ferreira [35]
28 p.A1020P Ala Pro 19 - 0.07318 0.110 Scheid [36]
29 p.A1020P Ala Pro 19 - 0.07318 0.110 Scheid [36]
30 p.T1098S Thr Ser 20 Exon: 2–24 0 0 Wang [26]
31 p.H1133Q His Gln 21 Exon: 2–23, intron 0.01022 0.0030 Abramycheva [34]
32 p.H1235L His Leu 22 Exon: 2–23 0.003990 0.0012 Ungaro [28]
33 p.L1515P Leu Pro 25 33 exons, intron 0 0 Fouillade [37]
34 p.V1762M Val Met 29 33 exons 0.0002146 - Bersano [38]
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This table shows the main genetic features of the 34 index patients: mutation, amino acid replaced,
amino acid substituent, exon where mutation is located, exons sequenced, minor allele frequency
(MAF) according to Exome Aggregation Consortium (ExAC), MAF according to 1000 Genomes Project,
author and reference.
2.1. Mutation Features
Twenty-five different cysteine-sparing NOTCH3 missense mutations were identified from the
34 patients described in the 18 papers analyzed (Table 1). A complete evaluation of the NOTCH3 exons
was carried out in 29% (8 out of 28) of the patients; therefore, in the other cases it was not possible
to rule out mutations involving cysteine residues. The mutations with the 33 exons analyzed were:
p.R61W [23]; p.R75P [25]; p.D80G [27]; p.G149V [29]; p.R213K [33]; p.L1515P [37]; and p.V1762M [38]
(Table 1).
Amino acid changes involving arginine were present in 44% of the patients, while those involving
proline were present in 26%. Only two mutations were found in exons that do not encode for the ECD:
p.L1515P [37] and p.V1762M [38], which encoded for the ICD.
The search for all mutations in Exome Aggregation Consortium (ExAC) and the 1000 Genomes
Project showed that only p.H1235L [28], p.H170R [30,31], p.S497L [34], p.A1020P [36],
and p.H1133Q [34] were polymorphisms or subpolymorphic variants, as their MAF was >0.1%.
2.2. Clinical Features
Of the 34 probands described in the 18 articles, 33% presented cardiovascular risk factors
such as smoking, hypertension, and/or dyslipidemia. Clinical symptoms included migraine
(93%), stroke (100%), seizures (60%), psychiatric disturbances (100%), pseudobulbar palsy (80%),
and dementia (94%), and gait disturbance was specified in four cases. A family history of stroke
and/or dementia was observed in 96% of the probands (Table 2).
The neuroimaging data revealed that all probands had severe WMH, although 91% did not have
anterior temporal pole involvement.
GOM deposits were found in six out of nine probands (67%). In two of these cases, they were
also found in the proband’s siblings. Specifically, mutations with GOM were: p.R61W [23] in the
symptomatic proband’s siblings, who had the same mutation; p.R75P [24–26]; p.D80G [30] in the
symptomatic proband’s siblings, who had the same mutation; p.R213K [33], p.A1020P [36] (in one
of the two probands); and p.T1098S [26]. However, three out of nine probands had cysteine-sparing
NOTCH3 missense mutations not associated with GOM: p.A1020P [33] (in one of two probands),
p.L1515P [34] and p.V1762M [35]; the latter two were mutations located in the ICD.
A summary of the main characteristics of cysteine-sparing NOTCH3 missense mutations is given
in Table 3.
The table not only summarizes the main characteristics of cysteine-sparing NOTCH3 missense
mutations, but also shows the five criteria required for mutations to be considered potentially
pathogenic: type of mutation, typical clinical CADASIL syndrome, diffuse WMH, whole exon analysis,
mutations that were not polymorphisms and GOM deposition, and the author.
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Table 2. Clinical and demographic data of the patients with cysteine-sparing NOTCH3 mutations.
Numb. Mutation Origin Sex Smoker(n=7)
HT
(n = 15)
DM
(n = 13)
Dyslip
(n = 11)
Clin.
Onset
(Years)
Migraine
(n = 15)
Stroke
(n =17)
Seizure
(n = 5)
Psych.
Disturb
(n = 8)
Pseudb.
Palsy
(n = 5)
Demen
(n = 18)
Gait
Distur
(n = 4)
FH a
(n = 25)
LETP b
(n = 11)
GOM
(n = 10) Author
1 p.R61W USA - Yes No No Yes 20 Yes Yes - - - - - Yes No * Brass
2 p.R75P Korea M - Yes No No 53 - Yes - - - Yes - Yes - Yes Kim
3 p.R75P Korea F No No No No 47 - Yes - - - - - Yes - - Kim
4 p.R75P Korea M No Yes No No 65 - Yes - - - Yes - Yes - - Kim
5 p.R75P Japan F - - - - - - Yes Yes Yes Yes - - Yes No - Mizuno
6 p.R75P Japan F - - - - - - Yes Yes - Yes - - Yes No Yes Mizuno
7 p.R75P China M - - - - 34 - Yes - Yes - - - No No Yes Wang
8 p.D80G Germany F No No No No - No Yes - Yes - Yes Yes Yes Yes * Wollenweber
9 p.R107W Germany - - - - - - Yes - - - - Yes - Yes - - Ungaro
10 p.G149V China F No No No No 39 - Yes - - - - - Yes No - Ge
11 p.Q151E Italy - - - - - - Yes - - - - Yes - Yes - - Ungaro
12 p.Q151E Spain - - - - - - - Yes - - - - - - - - Ampuero
13 p.H170R Spain - - - - - - - Yes - - - - - - - - Ampuero
14 p.H170R Oceania - - - - - - - - - - - - - - - - Roy
15 p.A198T Italy - - - - - - Yes - - - - Yes - Yes - - Ungaro
16 p.A202V Oceania F - - - - - - - - - - - - - - - Roy
17 p.R207H Italy - - - - - - Yes - - - - Yes - Yes - - Ungaro
18 p.R213K Japan M - No No No 63 Yes Yes No - Yes Yes Yes Yes - - Uchino
19 p.R213K Japan M - No No No 10 Yes Yes - Yes Yes Yes Yes Yes - Yes Santa
20 p.V237M Japan F - No No No 71 - Yes No - No Yes Yes Yes - - Uchino
21 p.V252M Russia - - No No - - - - - - - - - - - - Abramycheva
22 p.E309K Italy - - - - - - Yes - - - - Yes - Yes - - Ungaro
23 p.S497L Russia - - No No - - - - - - - - - - - - Abramycheva
24 p.T577A Portugal - - - - - - - - - - - - - - - - Ferreira
25 p.R592S Italy - - - - - - Yes - - - - Yes - Yes - - Ungaro
26 p.V644D Italy - - - - - - Yes - - - - Yes - Yes - - Ungaro
27 p.S978R Portugal F - - - - - - Yes Yes Yes - Yes - - - - Ferreira
28 p.A1020P Germany F - Yes - - Adolesc Yes - - - - Yes - Yes No Yes Scheid
29 p.A1020P Germany F - Yes - - - - - - Yes - - - Yes No No Scheid
30 p.T1098S China M - - - - 39 - Yes - Yes - Yes - Yes No Yes Wang
31 p.H1133Q Russia - - No No - - - - - - - - - - - - Abramycheva
32 p.H1235L Italy - - - - - - Yes - - - - Yes - Yes - - Ungaro
33 p.L1515P France F No No No No 35 Yes Yes - - - - - Yes No No Fouillade
34 p.V1762M Italy F Yes - - Yes Childhd Yes - - Yes - No - Yes No No Bersano
Perc - - - 29% 27% 0% 18% - 93% 100% 60% 100% 80% 94% 100% 96% 9% 40% -
Numb: Number; Smoker: current/past smoker; HT: hypertension; DM: diabetes mellitus; Dyslip: dyslipidaemia; Clin. Onset: Clinical Onset; Psych.distur: psychiatric disturbance;
Pseudb.palsy: pseudobulbar palsy; Dem.: dementia; Gait distur: gait disturbance; GOM: Granular osmiophilic material; M: male; F: female; Adolesc: adolescence; Childhd: childhood;
Perc: percentage; a FH: family history; b LE TP: leukoencephalopathy with anterior temporal pole involvement; * GOM found in proband’s siblings, who were symptomatic.
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Table 3. Summary of the main characteristics of cysteine-sparing NOTCH3 missense mutations.
Number Mutation Typical Clinical CADASIL Syndrome WMH Whole Exon Analysis Mutation GOM Author
1 p.R61W Yes Yes Yes Yes * Brass
2 p.R75P Yes Yes No Yes Yes Kim
3 p.R75P Yes Yes No Yes - Kim
4 p.R75P Yes Yes No Yes - Kim
5 p.R75P Yes Yes Yes Yes - Mizuno
6 p.R75P Yes Yes Yes Yes Yes Mizuno
7 p.R75P Yes Yes No Yes Yes Wang
8 p.D80G Yes Yes Yes Yes * Wollenweber
9 p.R107W Yes Yes No Yes - Ungaro
10 p.G149V Yes Yes Yes Yes - Ge
11 p.Q151E Yes Yes No Yes - Ungaro
12 p.Q151E Yes Yes No Yes - Ampuero
13 p.H170R Yes Yes No No - Ampuero
14 p.H170R Yes NS No No - Roy
15 p.A198T Yes Yes No Yes - Ungaro
16 p.A202V Yes NS No Yes - Roy
17 p.R207H Yes Yes No Yes - Ungaro
18 p.R213K Yes Yes NS Yes - Uchino
19 p.R213K Yes Yes Yes Yes Yes Santa
20 p.V237M Yes Yes NS Yes - Uchino
21 p.V252M Yes Yes No Yes - Abramycheva
22 p.E309K Yes Yes No Yes - Ungaro
23 p.S497L Yes NS No No - Abramycheva
24 p.T577A NS NS NS Yes - Ferreira
25 p.R592S Yes Yes No Yes - Ungaro
26 p.V644D Yes Yes No Yes - Ungaro
27 p.S978R Yes Yes NS Yes - Ferreira
28 p.A1020P Yes Yes NS No Yes Scheid
29 p.A1020P Yes Yes NS No No Scheid
30 p.T1098S Yes Yes No Yes Yes Wang
31 p.H1133Q Yes NS No No - Abramycheva
32 p.H1235L Yes Yes No No - Ungaro
33 p.L1515P Yes Yes Yes Yes No Fouillade
34 p.V1762M Yes Yes Yes Yes No Bersano
WMH: white matter hyperintensities; GOM: Granular osmiophilic material; NS: not specified; * GOM were found in proband’s sibling, who was symptomatic.
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Therefore, we considered that p.R61W [23], p.R75P [25], p.D80G [27], andp.R213K [33] could
be potentially pathogenic mutations, because they were associated with typical clinical CADASIL
syndrome and extensive WMH in MRI, the 33 NOTCH3 exons were analyzed and no other potential
pathogenic mutations were found; they had an MAF < 0.1% (ExAC, 1000 Genomes Project) (confirming
that they are not common polymorphisms) and GOM deposits were observed in the skin biopsy.
(The criteria for considering mutations as potentially pathogenic are explained in the Material and
Methods section).
In relation to co-segregation of these potentially pathogenic mutations, Mizuno et al. [25] studied
the relatives of probands with the p.R75P mutation. Those with clinical CADASIL and typical MRI
findings had the same p.R75P mutation, and the asymptomatic relative did not carry the mutation.
For p.D80G, two sisters and one brother with clinical CADASIL typical syndrome and extensive
WMH shared the same mutation, and the other asymptomatic brother did not share it. In addition,
the symptomatic brother had GOM in his skin biopsy, unlike the asymptomatic one. Segregation
analysis was not performed for p.R61W or p.R213K.
Of the ten probands that carried one of these four mutations, 80% were Asian, 60% had the p.R75P
mutation and just one of the probands (p.D80G) had temporal pole involvement.
Polyphen-2 analysis indicated that p.R61W, p.D80G, and p.R75P could be possible damaging
mutations (Table 4).
Table 4. Polyphen-2 results and domain localization of the selected mutations.
Mutation Score Confidence Domain Prediction
R61W 0.773
Sensitivity: 0.76
EGF-like 1 Possibly damagingEspecificity: 0.86
R75P 0.884
Sensitivity: 0.71
EGF-like 1 Possibly damagingEspecificity: 0.89
D80G 0.694
Sensitivity: 0.78
EGF-like 2 Possibly damagingEspecificity: 0.85
R213K 0.171
Sensitivity: 0.89
EGF-like 5 BenignEspecificity: 0.72
3. Discussion
In this systematic review, we conducted a thorough search for cysteine-sparing NOTCH3 missense
mutations in patients with typical clinical CADASIL syndrome in order to determine whether these
mutations could be considered pathogenic and to describe the patients that carry this type of mutation.
We excluded nonsense and insertion/deletion mutations because they lead to a numerical cysteine
alteration, as Rutten et al. described in a previous article [8].
The literature and gene databases describe 34 patients with 25 different cysteine-sparing NOTCH3
missense mutations. These 25 mutations included two in exons that encode for the ICD. The patients
presented typical clinical CADASIL syndrome with migraine, psychiatric disturbances, early onset of
stroke and/or dementia, and diffuse WMH in the MRI.
We believe there are four possible pathogenic cysteine-sparing NOTCH3 missense mutations:
p.R61W [23], p.R75P [25], p.D80G [27], and p.R213K [33]. These mutations were located in EGF-like
repeats. We think they are possible pathogenic mutations because patients presented typical clinical
CADASIL syndrome and MRI profiles, no additional mutations were found in the gene, they do
not represent low-frequency polymorphisms or subpolymorphic variants, and GOM deposits were
found in their skin biopsy. A familial co-segregation was observed for p.R61W [23], p.D80G [27] and
p.R75P [8,25], but not for p.R213K, because symptomatic relatives were not evaluated. In addition,
Polyphen-2 analysis predicted that p.R61W, p.D80G, and p.R75P, but not p.R213K could be possibly
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damaging mutations. Taking into account the information published in the literature these mutations
can be considered possible pathogenic mutations.
Of the 10 probands with these four mutations and CADASIL patients with cysteine mutations,
non-significant clinical or demographic differences were observed in migraine, stroke, or dementia.
However, WMH in the anterior part of the temporal pole were practically absent in these
cysteine-sparing NOTCH3 missense mutations. As mentioned previously, WMH in the temporal
pole has a reported 89–95% sensitivity and 80–86% specificity for CADASIL in Caucasian patients [14]
and a prevalence of 44.8–71% [16] in Asian populations. Therefore, considering that 80% of patients
in the review were Asians, at least four to five patients with temporal pole involvement should be
expected in CADASIL due to cysteine mutations. Therefore, we believe that absent temporal pole
involvement could be a characteristic of cysteine-sparing NOTCH3 missense mutations.
Rutten et al. performed an extensive search of all types of NOTCH3 mutations in order to provide
information on their interpretation [8]. Regarding the cysteine-sparing NOTCH3 missense mutations,
they studied 10 articles with 11 different mutations corresponding to p.R61W, p.R75P, p.Q151E,
p.H170R, p.A202V, p.R213K, p.V237M, p.T577A, p.S978R, p.A1020P, and p.Y1098S. They concluded
that these mutations were not associated with CADASIL, but p.R75P fulfilled all their criteria: (1) a
complete evaluation of the NOTCH3 gene to rule out a typical cysteine-altering mutation in another
exon; (2) the mutations were not polymorphisms; (3) a familial co-segregation was proven; and (4) the
clinical diagnosis was confirmed through the observation of GOM deposits in the skin biopsy.
This systematic review updates the interesting work of Rutten et al. [8], taking into consideration
three of the four criteria that they applied, excluding the lack of familiar segregation criterion [8].
We were able to add new information and conclusions stemming from the publication of new articles
with a total of 25 different mutations, in contrast to the 11 found previously by Rutten et al. Of the four
mutations considered potentially pathogenic in our systematic review, p.R75P was already mentioned
by Rutten et al. in their reference to Mizuno et al. In this review, we added information from two
new articles with a total of four new patients. Regarding p.R213K, Rutten et al. did not consider this
mutation as potentially pathogenic because familial co-segregation was not proven. However, we did
not define familial co-segregation as an exclusion criterion because it is not always possible to analyze
relatives or there may be no live relatives.
The genetic analysis technique was not specified for p.R61W, so Rutten et al. suggested the
possibility of using a technique that would not detect other mutations.
Finally, p.D80G was not studied previously by Rutten et al., but applying their criteria and ours,
it is a pathogenic mutation.
In several cases, the conclusions of these articles are supported by bioinformatics and functional
studies that have revealed the possible pathogenic effect of the mutations [37,39]. Mizuno et al.
suggested that changes in NOTCH3 structure could be related to the replacement of an amino acid by
proline (without cysteine involvement), because three-dimensional structure studies have shown that
it helps to stabilize the β-sheet [25]. This may lead to a conformational change in the protein. Another
study observed that several of these atypical mutations were associated with structural changes
in the NOTCH3 receptor [39], similar to the mechanism observed for typical mutations involving
cysteines. Thus, in addition to changes in the number of cysteines, mutations involving other amino
acids could also lead to misfolding of the receptor. In the same way, in vitro studies with p.R75P,
p.D80G, and delta88–91 have shown significantly enhanced aggregation similar to that of cysteine
mutations [27].
With regard to limitations, we should consider the low number of cases reported so far, as well
as the high number of Asian reports that could skew the frequencies of different features in this
population. In order to avoid this last limitation, we compared some important characteristics (such as
the temporal pole affectation) to their frequency in the Asian population.
Another limitation is that the analyses of p.R213K [33] to rule out other mutations in the NOTCH3
gene were performed using single-strand conformational polymorphism (SSCP) analysis, which does
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not detect other mutations, unlike the standard and reliable Sanger sequencing. In the case ofp.R61W,
the genetic analysis technique was not specified.
Furthermore, we did not consider a small deletion (delta88–91) that does not directly involve a
cysteine residue in the ECD of NOTCH3 [39]. This would have enriched our review, but could have
compromised the reliability of our conclusions. This deletion was reported in an Italian family with
typical clinical CADASIL syndrome and diffuse WMH, without anterior temporal pole involvement.
In addition, the proband’s skin biopsy showed GOM deposits. This mutation was also observed in the
only symptomatic relative. The asymptomatic relatives did not carry any NOTCH3 mutations.
Another limitation was combining ECD and ICD mutations in our review. The aim here was
to review typical clinical CADASIL syndrome with cysteine-sparing NOTCH3 missense mutations
to determine whether they were associated with CADASIL. In any case, ICD mutations were not
considered pathogenic because GOM deposits were absent.
4. Materials and Methods
An extensive literature search was performed up to November 2016 on PubMed, Google Scholar,
EMBASE, LILACS, Trip Database, and the Cochrane Library, as well as in “The Human Gene Mutation
Database” (http://www.hgmd.cf.ac.uk/ac/index.php), with the key words: “CADASIL cysteine”,
“NOTCH3 cysteine”, and “NOTCH3 polymorphism”, in order to collect data about cysteine-sparing
NOTCH3 missense mutations that were associated with typical clinical CADASIL syndrome.
A total of 244 studies were found. Probands had typical clinical CADASIL syndrome and a
cysteine-sparing NOTCH3 missense mutation (Figure 1) in 18 articles. Studies that analyzed other
diseases or endophenotypes, such as patients with diffuse WMH instead of a typical clinical CADASIL
syndrome, were excluded.
Only those articles that described missense mutations confirming an absence of cysteine
involvement were selected. Therefore, nonsense, intronic, insertion, and deletion mutations were
excluded because they can lead to cysteine number alterations, through the shortening of the protein
(in the case of nonsense mutations) [40,41] and or through changes in the open reading frame (in the
case of insertion-deletions) as described previously [8,42].
In addition, we excluded several studies describing mutations that were already known
polymorphisms, suggesting a negative pathogenic role, as well as an article by Ueda et al. [16],
as it was difficult to identify who was the proband and who was the relative of the patient with the
typical clinical CADASIL syndrome.
We collected data on epidemiological, clinical, genetic, and neuroimaging characteristics, such as
temporal pole involvement, as well as existence of skin biopsies. We used the IBM SPSS statistics
software package, version 22, for the frequencies analysis.
Mutations were considered potentially pathogenic when they fulfilled the following criteria:
(1) the patients had typical clinical CADASIL syndrome; (2) the patients had diffuse WMH in MRI;
(3) the study analyzed the 33 exons of the NOTCH3 gene to rule out other pathogenic mutations; (4) the
mutation had a MAF < 0.1%, since CADASIL is a low prevalence disease and it is therefore necessary
to rule out low-frequency polymorphisms (MAF < 5%) and subpolymorphic variants (frequency
0.1–1.0%) that could represent rare variants and not disease-causing mutations. To establish the
MAF, we used the ExAC database, containing genetic information on 60,706 unrelated individuals
(http://exac.broadinstitute.org), and the 1000 Genomes Project database, containing the genetic
information of 1000 individuals from different ethnicities (http://www.internationalgenome.org/
1000-genomes-browsers/); and lastly (5) the patient had GOM deposits in the skin biopsy because
this represents a specificity of 100% for CADASIL diagnosis. Finally we analyzed with Polyphen-2
tool the pathogenic prediction of the selected mutations that we considered potentially pathogenic
(http://genetics.bwh.harvard.edu/pph2/).
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5. Conclusions
We believe that the cysteine-sparing NOTCH3 missense mutations p.R61W, p.R75P, p.D80G,
and p.R213K could be potentially pathogenic, and we found familial co-segregation forp.R61W,
p.R75P, and p.D80G. Different studies confirmed an altered NOTCH3 structure or proaggregatory
properties due to these changes. Thus, cysteine-sparing NOTCH3 missense mutations are associated
with typical clinical CADASIL syndrome and a typical MRI profile, mostly without anterior temporal
pole involvement.
Further studies are necessary to clarify the role of these cysteine-sparing NOTCH3 missense
mutations in CADASIL to be able to interpret them properly to reach a correct diagnosis. Likewise,
an improved understanding of this kind of mutation would be important to clarify whether other
mechanisms, apart from disulfide bond-mediated misfolding due to an odd number of cysteines,
play a major role in the development of CADASIL, such as a receptor misfolding produced by other
amino acids.
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